Skip to main content

Table 1 Comparison of patient characteristics

From: Differential efficacy of cisplatin plus pemetrexed between L858R and Del-19 in advanced EGFR-mutant non-squamous non-small cell lung cancer

Patient characteristics All patients (n = 304) Del-19 (n = 36) L858R (n = 42) p-value
(Del-19/L858R)
Wild type (n = 226)
No. of patients % No. of patients % No. of patients %
Age (years)
 Median (range) 64.0 (37–78) 62.5 (41–77) 66.0 (38–78)   64.0 (37–78)
  < 65 160 20 55.6 17 40.5 0.18 123 54.4
  ≥ 65 144 16 44.4 25 59.5   103 45.6
Gender
 Male 216 19 52.8 15 35.7 0.13 182 80.5
 Female 88 17 47.2 27 64.3   44 19.5
PS (ECOG)
 0–1 273 35 97.2 40 95.2 0.65 198 87.6
 2 31 1 2.8 2 4.8   28 12.4
Smoking history
 Never 85 20 55.6 30 71.4 0.15 35 15.5
 Ever 219 16 44.4 12 28.6   191 84.5
Clinical stage
 IIIB, IV 277 30 83.3 35 83.3 1.00 212 93.8
 Recurrence 27 6 16.7 7 16.7   14 6.2
Histology
 Adenocarcinoma 276 34 94.4 42 100 0.30 200 88.5
 Large cell carcinoma 4 1 2.8 0 0   3 1.3
 NSCLC-NOS 24 1 2.8 0 0   23 10.2
Induction therapy cycles
 Mean (range) 3.7(1–6) 3.7 (1–6) 4.0 (1–6) 0.23 3.6 (1–6)
Maintenance therapy cycles
 Mean (range) 3.3(0–30) 4.1 (0–30) 6.0 (0–22) 0.17 2.7 (0–30)
  1. Del-19 19 deletion; L858R Leu858Arg; PS performance status
  2. ECOG Eastern Cooperative Oncology Group
  3. NSCLC-NOS non small cell lung cancer-not otherwise specified